Hopp til hovedinnhold

Covid-19

Sist revidert:
Sist revidert av:

Definisjon:
Virusinfeksjon som primært rammer luftveiene, forårsaket av koronavirus SARS-CoV-2
Forekomst:
Oppdaget i januar 2020 i Wuhan, Kina. Pandemisk siden mars 2020. Oversikt over den globale smittespredningen se verdenskart fra WHO 
Symptomer:
Den klassiske symptomtriaden består av feber, utmattelse og tørrhoste. Ellers varierende fra asymptomatiske forløp til milde symptomer på luftveisinfeksjon og/eller nedsatt smak- og luktesans, influensalignende symptomer, ev. magesmerter, diaré, oppkast, symptomer på pneumoni, lungesvikt og sepsis
Funn:
Ofte få eller ingen kliniske funn. Ev. økt resp. frekvens, lungefysikalia, tegn på respiratorisk svikt, sepsis, sjokk 
Diagnostikk:
PCR. Penselprøve fra svelg og nasofarynks, ev. prøvetaking fra nedre luftveier. Serologisk diagnostikk i tvilstilfeller. Hurtigtests har varierende kvalitet. Rtg. eller CT thorax kan vise pneumoni
Behandling:
Isolat og andre smitteverntiltak. Støttende behandling med væske- og ev. respiratorbehandling. Ev. antiviral behandling. Ev. kortikosteroider, kun ved alvorlige tilfeller. Vaksinering av befolkningen som forebyggende behandling
  1. European Centre for Disease Prevention and Control (ecdc). Situation updates on COVID-19. www.ecdc.europa.eu  
  2. Folkehelseinstituttet. Statistikk om koronavirus og covid-19. Sist oppdatert 22.04.2022. www.fhi.no  
  3. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. Ann Intern Med. 2021 May;174(5):655-662. 2021 Jan 22. PMID: 33481642;
  4. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020 Feb 25;323(8):707-708. PMID: 31971553. PubMed  
  5. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar;19(3):141-154. Epub 2020 Oct 6. PMID: 33024307; PMCID: PMC7537588.
  6. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. NEJM 2020; Epub: Jan 24. doi:10.1056/NEJMoa2001017 DOI  
  7. Holmes EC, Goldstein SA, Rasmussen AL, et al. The origins of SARS-CoV-2: A critical review. Cell. 2021 Sep 16;184(19):4848-4856. Epub 2021 Aug 19. PMID: 34480864 PubMed  
  8. European Centre for Disease Prevention and Control. SARS-CoV-2 variants dashboard. www.ecdc.europa.eu  
  9. Folkehelseinstituttet. Fakta om koronaviruset SARS-CoV-2 og sykdommen covid-19. Sist oppdatert 07.02.2022. www.fhi.no  
  10. Boban M. Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. Int J Clin Pract. 2021 Apr;75(4):e13868. Epub 2020 Dec 6. PMID: 33244856 PubMed  
  11. Folkehelseinstituttet. Molekylær diagnostikk av SARS-Cov-2. Sist oppdatert 29.03.2021. www.fhi.no  
  12. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020. pmid:32235945 PubMed  
  13. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020 Apr 28;9(1):45. PMID: 32345362 PubMed  
  14. Lee HW, Yoon CH, Jang EJ, Lee CH. Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis. Thorax. 2021 Jan 27:thoraxjnl-2020-215322. doi: 10.1136/thoraxjnl-2020-215322. Epub ahead of print. PMID: 33504565 PubMed  
  15. Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020 Oct;50(3):499-511. PMID: 32700024 PubMed  
  16. Liu JM, Tan BH, Wu S, Gui Y, Suo JL, Li YC. Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS-CoV-2 infection. J Med Virol. 2021 Mar;93(3):1304-1313. Epub 2020 Oct 14. PMID: 33002209 PubMed  
  17. Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021 Feb;76(2):428-455. Epub 2020 Dec 4. PMID: 33185910 PubMed  
  18. Chen S, Zheng T, Wang S, Yu Y, Wang P, Song Y, Jiang J. Association between risk of VTE and mortality in patients with COVID-19. Int J Infect Dis. 2021 Jun 6:S1201-9712(21)00494-X. Epub ahead of print. PMID: 34107325 PubMed  
  19. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2021 Feb;49(1):15-28. Epub 2020 Aug 28. PMID: 32860214 PubMed  
  20. Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2021 Jul;48:100785. Epub 2020 Dec 8. PMID: 33309392 PubMed  
  21. Bastard P, Rosen LB, Zhang Q, Eleftherios M. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020. pmid:32972996 PubMed  
  22. Direktoratet for e-helse. Kodeverk. ICPC-2. Den internasjonale klassifikasjonen for primærhelsetjenesten. Kodeveiledning. Siden besøkt 04.05.2020. ehelse.no  
  23. Helsedirektoratet. Nasjonal veileder. Koronavirus - beslutninger og anbefalinger. Kapittel 9.1 Allmennlegetjenesten. Siden besøkt 26.04.2022. www.helsedirektoratet.no  
  24. Direktoratet for e-helse. Kodeverk. ICD-10. U07.1 og U07.2 finnkode.ehelse.no  
  25. Folkehelseinstituttet. Definisjon av mistenkt, sannsynlig og bekreftet tilfelle av covid-19, samt definisjon av nærkontakter. Sist oppdatert 22.12.2020. www.fhi.no  
  26. Beeching NJ, Fletcher TE, Fowler R. Coronavirus disease 2019 (COVID-19). BMJ Best Practice. Last updated 07 Apr 2022. bestpractice.bmj.com  
  27. Hjelmesæth J, Skaare D. Covid-19 med nedsatt lukte- og smakssans som eneste symptom. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0287 DOI  
  28. Esmaeili M, Abdi F, Shafiee G, Asayesh H, Abdar ZE, Baygi F, Qorbani M. Olfactory and Gustatory Dysfunction in 2019 Novel Coronavirus: An Updated Systematic Review and Meta-analysis. Int J Prev Med. 2021 Dec 14;12:170. PMID: 35070203 PubMed  
  29. Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20(4):493-506. Pmid: 32720223 PubMed  
  30. Tveita A, Hestenes S, Sporastøyl ER, et al. Lungeembolisme ved covid-19. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0366 DOI  
  31. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med 2020. doi:10.1056/NEJMc2009787 DOI  
  32. Sellevoll HB, Saeed U, Young VS, et al. Covid-19 med akutte magesmerter som debutsymptom. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0262 DOI  
  33. Smith V, Seo D, Warty R, Payne O, Salih M, Chin KL, Ofori-Asenso R, Krishnan S, da Silva Costa F, Vollenhoven B, Wallace E. Maternal and neonatal outcomes associated with COVID-19 infection: A systematic review. PLoS One. 2020 Jun 4;15(6):e0234187. doi: 10.1371/journal.pone.0234187. PMID: 32497090 PubMed  
  34. Drammen GF, Greve-Isdahl M, Helbig A et al. Koronavirus ved svangerskap og fødsel. Norsk Gynekologisk Forening. Versjon 7, 22.03.2022. Siden besøkt 26.04.2022 www.legeforeningen.no  
  35. Pediatriveiledere. Fra Norsk barnelegeforening. Generell veileder. 3.28 COVID-19: SARS-Coronavirus-2 infeksjon hos barn. Revidert 2020-2021. Siden besøkt 26.04.2022. www.helsebiblioteket.no  
  36. Molteni E, Sudre CH, Canas LS, et al.. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021 Aug 3:S2352-4642(21)00198-X. Epub ahead of print. PMID: 34358472.
  37. Myrstad M, Ihle-Hansen H, Tveita AA, et al. National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - a prospective cohort study. Scand J Trauma Resusc Emerg Med. 2020;28(1):66. Published 2020 Jul 13. Pmid: 32660623 PubMed  
  38. Folkehelseinstituttet. Om koronatest. Publisert 06.04.2022. Siden besøkt 25.04.2022. www.fhi.no  
  39. FHI. Koronavirus - fakta, råd og tiltak. Antigen-hurtigtester. Sist oppdatert 07.04.2022. www.fhi.no  
  40. FHI. Koronavirus - fakta, råd og tiltak. Kriterier for melding og varsling av covid-19. Sist oppdatert 02.03.2022. Siden besøkt 27.04.2022. www.fhi.no  
  41. Kucirka LM, Lauer SA, Laeyendecker O, et al.:Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med 2020;May 13:Epub ahead of print. www.acc.org  
  42. Mustafa Hellou M, Górska A, Mazzaferri F, et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis published online ahead of print, 2020 Nov 11. Clin Microbiol Infect. 2020;S1198-743X(20)30695-9. Pmid: 33188933 PubMed  
  43. FHI. Koronavirus - fakta, råd og tiltak. Serologi og antistoff hurtigtester. Sist oppdatert 27.09.2021. www.fhi.no  
  44. Böger B, Fachi MM, Vilhena RO, et al. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. Am J Infect Control. 2020 Jul 10. pii: S0196-6553(20)30693-3. Pmid: 32659413 PubMed  
  45. The Centre for Evidence-Based Medicine. What is the efficacy and safety of rapid exercise tests for exertional desaturation in covid-19? April 21, 2020. Siden besøkt 11.05.2020. www.cebm.net  
  46. Folkhälsomyndigheten. Diagnostik av coronavirus 2019-nCoV, ett nytt virus som orsakat ett utbrott av allvarlig lunginflammation i Kina. Hämtad 2020-01-29
  47. Aaløkken TM, Parkar AP, Markussen TV. Bildediagnostikk av pasienter med covid-19. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0332 DOI  
  48. Guan WJ, Ni ZY, Hu Y, et al.. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; Feb 28: Epub ahead of print. pmid:32109013 PubMed  
  49. S Inui, A Fujikawa, M Jitsu. Chest CT Findings in Cases from the Cruise Ship “Diamond Princess” with Coronavirus Disease 2019 (COVID-19). Cardiothoracic Imaging. Vol. 2, No. 2. 2020 pubs.rsna.org  
  50. Wang Y, Liu Y, Liu L, et al. Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China. J Infect Dis. 2020 May 11;221(11):1770-1774. PMID: 32179910 PubMed  
  51. Sun Z, Zhang N, Li Y, et al. A systematic review of chest imaging findings in COVID-19. Quant Imaging Med Surg. 2020 May;10(5):1058-1079. Pmid: 32489929. PubMed  
  52. Socialstyrelsen. Rehabilitering i samband med covid-19 i primärvården. 2020-05-15 Dnr 4.3-14599/2020. www.socialstyrelsen.se  
  53. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. Published 2020 Aug 11. PMID: 32784198 PubMed  
  54. Norsk forening for infeksjonsmedisin. Antivirale og immunmodulerende midler ved COVID-19. Oversikt over aktuelle behandlingsmuligheter for pasienter innlagt ved norske sykehus, V13, 20.01.2022 www.legeforeningen.no  
  55. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. Published 2020 Jul 30. doi:10.1136/bmj.m2980. Pmid: 32732190.
  56. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022 Apr 14;386(15):1397-1408. Epub 2022 Feb 16. PMID: 35172054 PubMed  
  57. Helsedirektoratet. Nasjonal veileder. Koronavirus - beslutninger og anbefalinger. Kapittel 7.3 Legemidler, vaksiner og smittevernutstyr. Siden besøkt 28.02.2022.
  58. Reis G, dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022. pmid:34717820 PubMed  
  59. Robb CT, Goepp M, Rossi AG, Yao C. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020 Nov;177(21):4899-4920. Epub 2020 Aug 27. PMID: 32700336 PubMed  
  60. Ledford H. Nature. News. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. 16. June 2020. www.nature.com  
  61. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis published online ahead of print, 2020 Sep 2. JAMA. 2020;10.1001/jama.2020.17023. PMID: 32876694 PubMed  
  62. Shuto H, Komiya K, Yamasue M, et al. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Sci Rep. 2020;10(1):20935. Published 2020 Dec 1. Pmid: 33262415. PubMed  
  63. Lamontagne F, Agoritsas T, Macdonald H, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. Published 2020 Sep 4. doi:10.1136/bmj.m3379. PMID: 32887691. PubMed  
  64. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet 2021. PMID: 33844996 PubMed  
  65. BMJ News. BMJ 2021;373:n957. (Published 12 April 2021) doi.org  
  66. Rashid RA, Zgair A, Al-Ani RM. Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study. Am J Otolaryngol. 2021 Apr 7;42(5):103033. doi: 10.1016/j.amjoto.2021.103033. Epub ahead of print. PMID: 33839489 PubMed  
  67. Piechotta V, Iannizzi C, Chai KL, et al.. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub4 DOI  
  68. Fan AY, Gu S, Alemi SF; Research Group for Evidence-based Chinese Medicine. Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. J Integr Med. 2020 Sep;18(5):385-394. Epub 2020 Jul 31. PMID: 32792254 PubMed  
  69. Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep. 2021;11(1):8059. Published 2021 Apr 13. Pmid: 33850184 PubMed  
  70. Fiolet T, Guihur A, Rebeaud ME, et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2020 Aug 26:S1198-743X(20)30505-X. Epub ahead of print. PMID: 32860962 PubMed  
  71. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May 14;369:m1849. doi: 10.1136/bmj.m1849. DOI  
  72. Regjeringen.no. WHOs globale koronastudie starter i Norge Nyhet | Dato: 27.03.2020. www.regjeringen.no  
  73. WHO. "Solidarity" clinical trial for COVID-19 treatments. www.who.int  
  74. WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. Publisert 15. Oct. 2020. www.medrxiv.org  
  75. Lai CC, Chen CH, Wang CY, et al. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021 Mar 24:dkab093. Epub ahead of print. PMID: 33758946.
  76. Prasad M, Elavarasi A, Madan K, et al.. Efficacy and safety of antivirals for Covid-19: A systematic review and meta-analysis. Natl Med J India. 2020 Jul-Aug;33(4):222-231. PMID: 34045377 PubMed  
  77. Ader F, Bouschambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2022; 22: 209-221. pmid:34534511 PubMed  
  78. Alhumaid S, Mutair AA, Alawi ZA, et al. Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2020 Nov 28;5(4):180. PMID: 33260553 PubMed  
  79. Malgie J, Schoones JW, Pijls BG. Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies published online ahead of print, 2020 Sep 23. Clin Infect Dis. 2020;ciaa1445. Pmid: 32964913 PubMed  
  80. Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial published online ahead of print, 2020 Oct 20. JAMA Intern Med. 2020; Pmid: 33080017 PubMed  
  81. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 published online ahead of print, 2020 Oct 21. N Engl J Med. 2020; Pmid: 33085857 PubMed  
  82. Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial published online ahead of print, 2020 Dec 24. Eur Respir J. 2020;2003725. Pmid: 33361100 PubMed  
  83. Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection A Randomized Clinical Trial. JAMA 2021; 326: 490-8. pmid:34269813 PubMed  
  84. Butler CC, Yu LM, Dorward J, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med. 2021. PMID: 34329624 PubMed  
  85. Popp M, Stegemann M, Metzendorf M-I, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID‐19. Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No.: CD015017. DOI: 10.1002/14651858.CD015017.pub2. Accessed 24 August 2021 The Cochrane Library  
  86. López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial. JAMA 2021; 325: 1426-35. pmid:33662102 PubMed  
  87. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med 2021. pmid:34672950 PubMed  
  88. Liu K, Zhang W, Yang Y, et al. Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study. Complement Ther Clin Pract. 2020 May;39:101166. doi: 10.1016/j.ctcp.2020.101166. Epub 2020 Apr
  89. Walker A, Pottinger G, Scott A, Hopkins C. Anosmia and loss of smell in the era of covid-19. BMJ. 2020;370:m2808. Published 2020 Jul 21. Pmid: 32694187 PubMed  
  90. Hopkins C, Alanin M, Philpott C, et al. Management of new onset loss of sense of smell during the COVID-19 pandemic - BRS Consensus Guidelines. Clin Otolaryngol. 2021 Jan;46(1):16-22. Epub 2020 Sep 24. PMID: 32854169 PubMed  
  91. Liang M, Gao L, Cheng C, et al. Efficacy of face mask in preventing respiratory virus transmission: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 May 27:101751.Pmid: 32473312 PubMed  
  92. Bartoszko JJ, Farooqi MAM, Alhazzani W, et al. Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: A systematic review and meta-analysis of randomized trials. Influenza Other Respir Viruses. 2020 Apr 4. Pmid: 32246890 PubMed  
  93. Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020 Jun 1. pii: S0140-6736(20)31142-9. Pmid: 32497510. PubMed  
  94. Grove A, Osokogu O, Al-Khudairy L, et al.. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review. BMJ Open. 2021 May 28;11(5):e043737. PMID: 34049903 PubMed  
  95. McIntosh K. COVID-19: Clinical features. UpToDate. Last updated Feb. 18, 2021. www.uptodate.com  
  96. Cariou, B., Hadjadj, S., Wargny, M. et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia (2020). https://doi.org/10.1007/s00125-020-05180-x
  97. FHI. COVID-19-EPIDEMIEN: Risiko, prognose og respons i Norge etter uke 12. Folkehelseinstituttet, 24.03.2020. www.fhi.no  
  98. Ludvigsson JF. Systematic review of COVID‐19 in children show milder cases and a better prognosis than adults. Acta Paediatr. Accepted Author Manuscript. 2020. doi:10.1111/apa.15270 DOI  
  99. Villar J, Ariff S, Gunier RB et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021 Aug 1;175(8):817-826. PMID: 33885740 PubMed  
  100. Gorzkowski V, Bevilacqua S, Charmillon A, et al. Evolution of Olfactory Disorders in COVID-19 Patients published online ahead of print, 2020 Jul 2. Laryngoscope. 2020;10.1002/lary.28957. Pmid: 32617990 PubMed  
  101. Katsoularis I, Fonseca-Rodiguez O, Farrington P, et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: A self-controlled case series and matched cohort study. Lancet 2021. PMID: 34332652 PubMed  
  102. Gnecchi M, Moretti F, Bassi EM, et al. Myocarditis in a 16-year-old boy positive for SARS-CoV-2. Lancet 2020; 395: Epub June 27. doi:10.1016/S0140-6736(20)31307-6 DOI  
  103. Läkartidningen. 2020;117:20094 lakartidningen.se  
  104. Viner RM, Whittaker E. Kawasaki-like Disease: Emerging Complication During the COVID-19 Pandemic. Lancet 2020. pmid:32410759 PubMed  
  105. Patel P, De Cuir J, Abrams J, et al. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults A Systematic Review. JAMA Netw Open 2021. doi:10.1001/jamanetworkopen.2021.26456 DOI  
  106. Juvet LK, Laake I, Vestrheim DF: Letalitet og infeksjonsletalitet for alvorlig Covid-19 – 1. oppdatering – en hurtigoversikt. Hurtigoversikt 2020. Oslo: Folkehelseinstituttet, mai 2020. www.fhi.no  
  107. Public Health England. Past COVID-19 infection provides some immunity but people may still carry and transmit virus. Press release, 14. Jan 2021. www.gov.uk  
  108. Flodgren GM, Immunity after SARS-CoV-2 infection. Rapid review 2020. Oslo: Norwegian Institute of Public Health, 2020. legehandboka.no  
  109. Edridge A, Kaczorowska JM, Hoste A et al. Human coronavirus reinfection dynamics: lessons fo r SARS-CoV-2.medRxiv 2020.05.11.20086439; doi: https://doi.org/10.1101/2020.05.11.20086439
  110. Levin AT, Hanage WP, Owusu-Boaitey N, et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020 Dec;35(12):1123-1138. Epub 2020 Dec 8. PMID: 33289900 PubMed  
  111. Dyer O. Covid-19: Delta infections threaten herd immunity vaccine strategy BMJ 2021; 374 :n1933 doi:10.1136/bmj.n1933 DOI  
  112. Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care. 04 April 2020 www.icnarc.org  
  113. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med 2020. pmid:32558485 PubMed  
  114. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al.. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021 Aug 9;11(1):16144. PMID: 34373540 PubMed  
  115. Yee J, Kim W, Han JM, et al. Clinical manifestations and perinatal outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. Sci Rep. 2020;10(1):18126. Published 2020 Oct 22. PMID: 33093582 PubMed  
  116. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. Published 2020 Sep 1. PMID: 32873575 PubMed  
  117. Ahlberg M, Neovius M, Saltvedt S, et al. Association of SARS-CoV-2 Test Status and Pregnancy Outcomes published online ahead of print, 2020 Sep 23. JAMA. 2020;e2019124. Pmid: 32965467 PubMed  
  118. Son M, Gallagher K, Lo JY, et al.. Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy Outcomes in a U.S. Population. Obstet Gynecol. 2021 Aug 9. Epub ahead of print. PMID: 34433180.
  119. Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021 Apr 19;193(16):E540-E548. Epub 2021 Mar 19. PMID: 33741725 PubMed  
  120. Drammen GF, Greve-Isdahl M, Sitras V et al. Koronavirus ved svangerskap og fødsel. Norsk Gynekologisk Forening. Oslo; 24.11.2020. Sist oppdatert 30.08.2021. Siden besøkt 06.10.2021 www.legeforeningen.no  
  121. Bwire GM, Njiro BJ, Mwakawanga DL, Sabas D, Sunguya BF. Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: A living systematic review published online ahead of print, 2020 Oct 22. J Med Virol. 2020;10.1002/jmv.26622. Pmid: 33090535 PubMed  
  122. Kotlyar A, Grechukhina O, Chen A, et al. Vertical Transmission of COVID-19: A Systematic Review and Meta-analysis published online ahead of print, 2020 Jul 30. Am J Obstet Gynecol. 2020;S0002-9378(20)30823-1. Pmid: 32739398 PubMed  
  123. Folkehelseinstituttet. Hva skal du gjøre hvis du er syk eller mistenker at du er smittet av koronavirus? Sist oppdatert 14.02.2021. www.fhi.no  
  124. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med. 2020 Sep 1;173(5):362-367. doi: 10.7326/M20-3012. Epub 2020 Jun 3. PMID: 32491919 PubMed  
  125. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-2261. Pmid: 32253535 PubMed  
  126. Goha A, Mezue K, Edwards P, et al. COVID-19 and the heart: An update for clinicians. Clin Cardiol. 2020 Nov;43(11):1216-1222. Epub 2020 Jun 12. PMID: 32533585 PubMed  
  127. Tessitore E, Carballo D, Pncet A, et al. Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease. Open Heart 2021; 8: e001526. pmid:33833064 PubMed  
  128. Anderson JL, May HT, Knight S, et al. Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population. JAMA Netw Open 2021; 4: e217429. doi:10.1001/jamanetworkopen.2021.7429 DOI  
  129. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science 2020. doi:10.1126/science.abb3221 DOI  
  130. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020. pmid:32104915 PubMed  
  131. Shen Z, Xiao Y, Kang L, et al . Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients. Clin Infect Dis 2020; Epub Mar 4: pii: ciaa203. pmid:32129843 PubMed  
  132. Andersen TK, Grødeland G. Vaksinene kan holde tritt med SARS-CoV-2-mutasjonene. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.21.0080 DOI  
  133. Lewis D. Superspreading drives the COVID pandemic - and could help to tame it. Nature. 2021 Feb;590(7847):544-546. PMID: 33623168. PubMed  
  134. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579. Published 2021 Mar 9. PMID: 33687922 PubMed  
  135. Tang JW, Toovey OTR, Harvey KN, Hui DDS. Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J Infect. 2021 Jan 17:S0163-4453(21)00030-X. Epub ahead of print. PMID: 33472093 PubMed  
  136. Toovey OTR, Harvey KN, Bird PW, Tang JWW. Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK. J Infect. 2021 Feb 3:S0163-4453(21)00047-5. Epub ahead of print. PMID: 33548358 PubMed  
  137. Mallapaty S, Maxmen A, Callaway E. ‘Major stones unturned’: COVID origin search must continue after WHO report, say scientists. Nature news. Publisert 10. feb. 2021. www.nature.com  
  138. Lewis D. COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? Nature. News feature. Publisert 29. jan. 2021. www.nature.com  
  139. van Doremalen N, Bushmaker T, Morris D, et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. medRxiv, the preprint server for health sciences. Doi.org/10.1101/2020.03.09.20033217 www.medrxiv.org  
  140. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-544. PMID: 32645347 PubMed  
  141. Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. N Engl J Med 2020. doi:10.1056/NEJMcp2009249 DOI  
  142. Sakurai A, Sasaki T, Kato S, et al. Natural History of Asymptomatic SARS-CoV-2 Infection (correspondance). NEJM, June 12, 2020. DOI: 10.1056/NEJMc2013020. www.nejm.org  
  143. He Z, Ren L, Yang J, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. The Lancet, published March 20, 2021. DOI:https://doi.org/10.1016/S0140-6736(21)00238-5
  144. Borén HK, Kjøstolfsen GH, Aaløkken TM, et al. En mann i 90-årene med feber og tørrhoste. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0218 DOI  
  145. Dagens Medisin. Molnupiravir kan bli tilgjengelig i 105 land etter ny lisensavtale. DM 28.10.2021 www.dagensmedisin.no  
  146. Statens legemiddelverk. Status for kommende vaksiner. Siden besøkt 05.03.2021 legemiddelverket.no  
  • Peter D. Jost, spesialist i allmennmedisin, redaktør NEL